Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B

Henry Ford Health System36 enrolled

Overview

Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not severely ill. Recently particular polymorphisms of IL-28B gene were reported to correlate with histological recurrence and antiviral treatment response after orthotopic liver transplantation for hepatitis C. Similar results have not been described yet in living donor liver transplant patients. There is data suggesting slightly inferior outcomes in living donor liver transplants when done for hepatitis C. The investigators postulate that such inferior outcomes may be related to IL28 polymorphism concordance (i.e., unfavorable recipient polymorphism patients receive similarly unfavorable polymorphism livers from their relatives).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatitis C

Interventions

Interleukin 28B genotypeGENETIC

Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who received a living donor liver transplant for chronic hepatitis C who are 18 year or older * Patients who donated part of their liver to patients suffering from chronic hepatitis C. Donors must be 18 years or older Exclusion Criteria: * Patients who are not willing to sign the consent * Inability to obtain liver specimen (recipients) * Inability to obtain blood sample (donors)

Outcomes

Primary Outcomes

Sustained virological response after living donor liver transplant

Determine if sustained virological response is achieved after liver transplantation for hepatitis C with antiviral therapy (rivabirin and pegelated interferon) based on patient IL28B genotype

Time frame: 12-24 months

Secondary Outcomes

Liver retransplantation

Determine the need of liver retransplantion based on the IL 28B genotype

Time frame: 1-24 months